Supplementary Information

Title: Efficacy and Safety of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis of RCTs

Authors: Pasion Emily Noelle[1], Fischer Joseph[2], Alice Tsao[3], Thomas Pashalides[3], Mohd Razaleigh Yusof[4], Muhammad Uzair[5], Liaqat Ali[6]

[1] Department of Internal Medicine, California Northstate University College of Medicine, Elk Grove, CA, US

[2] College of Biological Sciences, University of California, Davis, CA, US

[3] Department of Urology, Kaiser South Sacramento Medical Center, Sacramento, CA, US

[4] Department of Urology, Hospital Sultan Abdul Aziz Shah, Serdang, Selangor, Malaysia

[5] Department of Laboratory Service, Star Diagnostic Center, Peshawar, Pakistan

[6] Institute of Kidney Diseases, Hayatabad Medical Complex, Khyber Girls Medical College, Peshawar, Pakistan

Correspondence: Liaqat Ali

Address: Hmc, Phase-4 Phase 4 Hayatabad, Peshawar, 25100, Pakistan

Institute of Kidney Diseases, Hayatabad Medical Complex, Khyber Girls Medical College

Tel: +92 91 9217261

Email: liaqat_99@yahoo.com

Table S1: Detailed Search Strategies for Each Database

Databases	Search Formula
Web of Science	TS=("urothelial carcinoma" OR "bladder cancer") AND TS=("neoadjuvant chemotherapy") AND TS=("randomized clinical trial")
PubMed	(((urothelial carcinoma) OR (bladder cancer)) AND (neoadjuvant chemotherapy)) AND (randomized clinical trial)
Cochrane Library	("urothelial carcinoma" OR "bladder cancer") AND "neoadjuvant chemotherapy" AND "randomized controlled trial":ti,ab,kw
Embase	("urothelial carcinoma" OR "bladder cancer") AND "neoadjuvant chemotherapy" AND "randomized clinical trial"

Figure S1: Flowchart of Enrolled Studies






Figure S2: Funnel plot of Enrolled Studies on Pathological Complete Response




ddMVAC: dose- dense methotrexate, vinblastine, doxorubicin, and cisplatin; MVAC: methotrexate, vinblastine, doxorubicin, and cisplatin; GC: gemcitabine and cisplatin; MC: methotrexate and cisplatin; RC: radical cystectomy

Figure S3: Ranking the Probability of each regimen based on 1,000 Simulations for pCR




ddMVAC: dose- dense methotrexate, vinblastine, doxorubicin, and cisplatin; MVAC: methotrexate, vinblastine, doxorubicin, and cisplatin; GC: gemcitabine and cisplatin; MC: methotrexate and cisplatin; RC: radical cystectomy

Figure S4: Funnel plot of Enrolled Studies on Overall Survival



GC-D gemcitabine, cisplatin, and durvalumab; MVAC: methotrexate, vinblastine, doxorubicin, and cisplatin; GC: gemcitabine and cisplatin; MC: methotrexate and cisplatin; RC: radical cystectomy

Figure S5: Ranking the possibility of Each Regimen Based on 1,000 Simulations for OS



GC-D gemcitabine, cisplatin, and durvalumab; MVAC: methotrexate, vinblastine, doxorubicin, and cisplatin; GC: gemcitabine and cisplatin; MC: methotrexate and cisplatin; RC: radical cystectomy

Figure S6: Risk of Bias

